Patient Capital Management, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001854794

What is a 13F filing? Who files one and when · What 13F filings can't tell you

Samantha McLemore — tracked via quarterly SEC 13F filings · All famous investors

MidHigh Turnover how tags are computed

Q2 2026 · 39 positions · Total reported value $2.99B · Top-10 concentration 52.4% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 69.0% · 3 new · 23 cut · 3 exited

Active Share (vs S&P 500): 80.6% · vs QQQ: 81.3% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): +3.9% · vs SPY +1.8% · Prev Value $2.99B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -0.4% · vs SPY -2.6% · Latest Value $2.96B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2026 13F filing, Patient Capital Management, LLC disclosed 39 equity positions with a combined reported value of $2.99B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 52.4% of reported value. HoldingsHub classifies the profile as Mid / High Turnover.

The largest disclosed positions as of Q2 2026 were RPRX ($201.79M), C ($196.43M), GOOGL ($187.89M). By sector, the heaviest allocations are Consumer Discretionary 28.4%, Health Care 19.9%. Versus the prior quarter, allocation shifted toward Health Care (+2.5pp), Consumer Discretionary (+2.3pp) and away from Utilities (-0.5pp), Other (-1.5pp).

Versus the prior quarter, Patient Capital Management, LLC opened 3 new positions, trimmed 23 and fully exited 3, a turnover rate of 69.0% of positions. The portfolio's overlap with the prior quarter was 90% of names.

The largest new positions opened in Q2 2026 were GPN ($68.37M), GENI ($4.93M).

Of the 3 positions fully exited versus the prior quarter, the largest were IBIT ($42.26M), TSLA ($18.59M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • GPN GLOBAL PMTS INC · $68.37M
  • GENI GENIUS SPORTS LIMITED · $4.93M

Fully Exited (vs previous quarter)

  • IBIT ISHARES BITCOIN TR · prev qtr: $42.26M
  • TSLA TESLA INC · prev qtr: $18.59M

Insider Transactions (Form 4)

Latest Samantha McLemore buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Patient Capital Management, LLC is an SEC-registered 13F filer based in Baltimore, MD, United States. As of Q2 2026 it reported 39 US equity positions with a combined value of $2.99B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: BALTIMORE, MD, United States
  • SEC registration: 801-118170 (status: Approved), registered 2020-03-05
  • Regulatory AUM (Form ADV): $2.50B as of 2026-03-27
  • Client mix (by RAUM): registered investment companies 85%, pension and profit-sharing plans 9%
  • Manages 1 private funds, of which 1 hedge funds
  • Website: patientcapitalmanagement.com

Portfolio Structure

  • 39 positions · $2.99B reported value (Q2 2026)
  • Top 10 holdings = 52.4% of reported value
  • Largest position: RPRX (ROYALTY PHARMA PLC) at 6.8%
  • Average position size: $76.65M

Sector Tilt

  • Consumer Discretionary 28.4%
  • Health Care 19.9%
  • Financials 17.9%
  • (classified holdings cover 96% of value)

Quarterly Activity

  • Q2 2026: 2 new, 10 added, 18 reduced, 2 exited
  • 9 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

The Q2 2026 rebalance from Patient Capital Management signals a deliberate shift toward cyclical and recovery-oriented exposures while trimming several high-conviction quality names. The overall market view appears cautiously constructive but selective, reflecting a barbell approach: reducing positions perceived as overvalued or sensitive to fading growth trends, while adding names that benefit from reopening momentum, consumer spending resilience, and infrastructure tailwinds. The portfolio retains a heavyweight bias, with the top ten holdings comprising roughly half of the $2.99 billion total value, making the direction of each move impactful for overall risk and return profiles. Key adds and reduces reveal a clear thematic rotation. Reductions were concentrated in royalty pharma (RPRX), banking (C), big tech (GOOGL), and healthcare services (CVS), with CVS standing out at a 9.0% quarter-over-quarter trim, suggesting either profit-taking, deteriorating fundamentals such as generic pricing pressure, or a strategic exit from a position that had run significantly. In contrast, adds to Amazon (AMZN), Norwegian Cruise Line (NCLH), and QXO signal exposure to e-commerce/cloud stability, leisure travel recovery, and what appears to be energy or building-material infrastructure, respectively. The AMZN increase of 4.1% likely reflects continued confidence in AWS margins and consumer discretionary resilience, while NCLH’s 4.9% add bets on pent-up travel demand and seasonal strength. QXO’s 5.3% increase may target cyclical benefits from construction activity or commodity-linked demand. This rotation amounts to meaningful sector/style drift. The portfolio is moving away from traditional quality and defensive growth—financials, big pharma, large-cap internet services, and integrated healthcare—toward consumer cyclicals, technology with e-commerce diversification, and what may be value-oriented industrial or energy exposures. The weight concentration remains high, but the composition is shifting from “own the best” to “own the recovery,” which could underperform if macroeconomic momentum slows or if interest rates remain restrictive for longer than anticipated. The trimming of CVS also hints at potential headwinds in the broader healthcare sector, particularly around margin compression and regulatory scrutiny. Risk notes center on concentration and cyclical exposure. With nearly half the portfolio in ten names, any sustained decline in the largest holders—particularly RPRX, C, or GOOGL—would materially impact returns. The new positions in NCLH and QXO introduce sensitivity to consumer spending cycles and infrastructure spending variability, respectively. Additionally, the sharp reduction in CVS may foreshadow wider healthcare sector reassessment, and the overall move out of defensive quality into cyclicals raises the probability of underperformance in a downturn. Interest rate sensitivity in financials and rate-sensitive sectors further warrants monitoring as the monetary policy outlook evolves.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 19.9%
Financials 17.9%
Technology 17.5%
Utilities 3.9%
Energy 2.7%
Other 5.4%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 3.60M $201.79M 6.75%
6.75%
Reduce
2 1.40M $196.43M 6.57%
6.57%
Reduce
3 525.75K $187.89M 6.29%
6.29%
Reduce
4 437.77K $181.95M 6.09%
6.09%
Hold
5 681.05K $162.32M 5.43%
5.43%
Add
6 709.59K $141.98M 4.75%
4.75%
Hold
7 1.24M $127.81M 4.28%
4.28%
Reduce
8 6.03M $127.29M 4.26%
4.26%
Add
9 7.14M $123.32M 4.13%
4.13%
Add
10 6.08M $116.26M 3.89%
3.89%
Hold
11 2.43M $111.96M 3.75%
3.75%
Reduce
12 19.04M $108.51M 3.63%
3.63%
Add
13 731.52K $99.48M 3.33%
3.33%
Hold
14 799.43K $96.44M 3.23%
3.23%
Reduce
15 170.79K $96.20M 3.22%
3.22%
Hold
16 4.08M $83.61M 2.80%
2.80%
Add
17 361.13K $74.04M 2.48%
2.48%
Add
18 1.95M $73.88M 2.47%
2.47%
Reduce
19 942.31K $68.37M 2.29%
2.29%
New
20 462.02K $67.54M 2.26%
2.26%
Add
21 1.22M $62.16M 2.08%
2.08%
Add
22 345.31K $60.72M 2.03%
2.03%
Reduce
23 631.56K $48.68M 1.63%
1.63%
Reduce
24 953.73K $47.27M 1.58%
1.58%
Reduce
25 953.64K $46.78M 1.56%
1.56%
Reduce
26 167.81K $42.94M 1.44%
1.44%
Hold
27 702.37K $42.82M 1.43%
1.43%
Reduce
28 189.40K $40.92M 1.37%
1.37%
Add
29 431.21K $40.39M 1.35%
1.35%
Reduce
30 1.38M $35.10M 1.17%
1.17%
Reduce
31 1.51M $27.00M 0.90%
0.90%
Add
32 400.70K $23.21M 0.78%
0.78%
Reduce
33 29.36K $9.61M 0.32%
0.32%
Hold
34 812.82K $4.93M 0.17%
0.17%
New
35 100.00K $3.73M 0.12%
0.12%
Reduce
36 204.02K $2.33M 0.08%
0.08%
Reduce
37 50.00K $1.63M 0.05%
0.05%
Hold
38 12.50K $1.11M 0.04%
0.04%
Hold
39 1.06K $791.60K 0.03%
0.03%
Reduce

FAQ

What did Patient Capital Management, LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, Patient Capital Management, LLC reported 39 equity positions worth $2.99B in aggregate; its largest disclosed positions were RPRX ($201.79M), C ($196.43M), GOOGL ($187.89M).

How large is Patient Capital Management, LLC's portfolio?

Patient Capital Management, LLC reported $2.99B of long equity holdings across 39 positions as of 2026-Q2. Top-10 holdings account for 52.4% of reported value.

What is Patient Capital Management, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/patient-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →